Interpace Biosciences reports Q4 Molecular Volume up 21% year-over-year

Fourth quarter Molecular Volume increased 21% year-over-year compared to Q4 2023, and 17% for the Full Year resulting in double-digit Q4 and YTD revenue growth. “The Company achieved record test volume, test revenue, income, and cash collections in Q4 and full year 2024,” said Chris McCarthy, CFO. “The Company’s strategic focus on operational and efficiency improvements also delivered record gross and net income margins.”